

Vahid Asnafi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5389534/publications.pdf>

Version: 2024-02-01

101
papers

5,237
citations

76326

40
h-index

91884

69
g-index

106
all docs

106
docs citations

106
times ranked

6839
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenetic landscape of lymphomagenesis in coeliac disease. <i>Gut</i> , 2022, 71, 497-508.	12.1	48
2	Dynamics of broad H3K4me3 domains uncover an epigenetic switch between cell identity and cancer-related genes. <i>Genome Research</i> , 2022, 32, 1328-1342.	5.5	14
3	Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins. <i>Blood Cancer Journal</i> , 2022, 12, 14.	6.2	10
4	De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells. <i>Molecular Cancer</i> , 2022, 21, 65.	19.2	0
5	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2022, 35, 1227-1235.	5.5	5
6	Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype. <i>Leukemia</i> , 2021, 35, 764-776.	7.2	24
7	<i>IKZF1</i> alterations predict poor prognosis in adult and pediatric T-ALL. <i>Blood</i> , 2021, 137, 1690-1694.	1.4	8
8	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. <i>Leukemia</i> , 2021, 35, 724-736.	7.2	8
9	Adenylate kinase 2 expression and addiction in T-ALL. <i>Blood Advances</i> , 2021, 5, 700-710.	5.2	7
10	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. <i>Blood Advances</i> , 2021, 5, 1540-1551.	5.2	35
11	Integrated omics approaches to predict T-LBL relapse risk. <i>Blood</i> , 2021, 137, 2280-2282.	1.4	0
12	Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	13
13	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 74.	17.0	10
14	A DL-4- and TNF±-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1662-1676.	10.5	6
15	Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. <i>Leukemia</i> , 2021, , .	7.2	2
16	PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. <i>Blood</i> , 2021, 138, 1855-1869.	1.4	23
17	Toward Pediatric T Lymphoblastic Lymphoma Stratification Based on Minimal Disseminated Disease and NOTCH1/FBXW7 Status. <i>HemaSphere</i> , 2021, 5, e641.	2.7	5
18	Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	15

#	ARTICLE	IF	CITATIONS
19	Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, 1575-1581.	3.5	10
20	Preclinical efficacy of humanized, non- α -Fc γ 3R-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2020, 136, 1298-1302.	1.4	7
21	Arsenic trioxide (As ₂ O ₃) as a maintenance therapy for adult T cell leukemia/lymphoma. <i>Retrovirology</i> , 2020, 17, 5.	2.0	20
22	CBF β -SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2020, 30, 299-307.e3.	6.4	6
23	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. <i>Cell Reports</i> , 2020, 30, 739-754.e4.	6.4	32
24	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. <i>Leukemia</i> , 2020, 34, 1730-1740.	7.2	21
25	Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients. <i>Blood</i> , 2020, 136, 22-23.	1.4	0
26	Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 169-174.	2.5	9
27	Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 1008-1018.	1.5	18
28	GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF- κ B-Dependent Mechanism. <i>Cancer Cell</i> , 2019, 36, 268-287.e10.	16.8	34
29	Epigenetic Silencing Affects Asparaginase Sensitivity and Predicts Outcome in T-ALL. <i>Clinical Cancer Research</i> , 2019, 25, 2483-2493.	7.0	25
30	DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 1617-1625.	3.5	40
31	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1981-1988.	5.2	12
32	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	5.2	72
33	NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. <i>Gut</i> , 2019, 68, 1396-1405.	12.1	47
34	A comprehensive catalog of lncRNAs expressed in T-cell acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2002-2014.	1.3	4
35	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019, 133, 280-284.	1.4	48
36	The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL). <i>Blood</i> , 2019, 134, 1339-1339.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Novel Intergenically Spliced Chimera, <i>NFATC3-PLA2G15</i> , Is Associated with Aggressive T-ALL Biology and Outcome. <i>Molecular Cancer Research</i> , 2018, 16, 470-475.	3.4	3
38	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 289-300.	1.4	97
39	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2514-2523.	1.6	99
40	Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1878-1882.	7.2	8
41	Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. <i>Journal of Clinical Investigation</i> , 2018, 128, 3071-3087.	8.2	133
42	Longitudinal Evolution and Clinical Impact of Subclonal Mutational Architecture in Adult T Cell Leukemia/Lymphoma. <i>Blood</i> , 2018, 132, 2841-2841.	1.4	0
43	Acquired TET 2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of preleukaemic clone resulting in T2-ALL and AML-EMO. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1237-1242.	3.6	10
44	Response to 5-azacytidine in a patient with <i>TET2</i> -mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 864-868.	1.7	33
45	Homeobox protein TLX3 activates miR-125b expression to promote T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2017, 1, 733-747.	5.2	31
46	Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2683-2691.	1.6	134
47	Adult T cell leukemia aggressiveness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. <i>Oncotarget</i> , 2017, 8, 52256-52268.	1.8	20
48	An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. <i>Haematologica</i> , 2016, 101, 732-740.	3.5	53
49	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. <i>Haematologica</i> , 2016, 101, 336-345.	3.5	50
50	CD1d-restricted peripheral T cell lymphoma in mice and humans. <i>Journal of Experimental Medicine</i> , 2016, 213, 841-857.	8.5	19
51	Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. <i>Immunity</i> , 2016, 45, 610-625.	14.3	131
52	Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. <i>Cancer Discovery</i> , 2016, 6, 972-985.	9.4	33
53	Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. <i>Nature Communications</i> , 2016, 7, 10087.	12.8	65
54	Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LLO3 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 572-580.	1.6	76

#	ARTICLE	IF	CITATIONS
55	<i>t(11;22)(p15.5;q11)</i> is a rare recurrent translocation that is associated with <i>HOXA</i> activation and poor treatment response in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 470-473.	2.5	5
56	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016, 128, 762-762.	1.4	13
57	Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 65923-65936.	1.8	8
58	Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 2486-2496.	1.4	233
59	Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A french multicenter study. , 2015, 88, 21-29.		28
60	Quality assessment program for <i>EuroFlow</i> protocols: Summary results of four-year (2010-2013) quality assurance rounds. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 145-156.	1.5	144
61	Site- and allele-specific polycomb dysregulation in T-cell leukaemia. <i>Nature Communications</i> , 2015, 6, 6094.	12.8	47
62	Targeting IRAK1 in T-Cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 18956-18965.	1.8	16
63	RUNX1 as a recombinase cofactor. <i>Oncotarget</i> , 2015, 6, 21793-21794.	1.8	2
64	Semaphorin 3F and Neuropilin-2 Control the Migration of Human T-Cell Precursors. <i>PLoS ONE</i> , 2014, 9, e103405.	2.5	40
65	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 3739-3749.	1.4	281
66	RUNX1-dependent RAG1 deposition instigates human TCR- β locus rearrangement. <i>Journal of Experimental Medicine</i> , 2014, 211, 1821-1832.	8.5	19
67	Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients. <i>British Journal of Haematology</i> , 2014, 166, 50-59.	2.5	33
68	SET-NUP214 is a recurrent β lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. <i>Blood</i> , 2014, 123, 1860-1863.	1.4	40
69	Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. <i>Blood</i> , 2014, 124, 3023-3025.	1.4	21
70	Hijacking T-ALL. <i>Blood</i> , 2014, 124, 3038-3040.	1.4	2
71	Toward a NOTCH1/FBXW7/RAS/PTEN-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4333-4342.	1.6	202
72	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. <i>Haematologica</i> , 2013, 98, 1711-1717.	3.5	41

#	ARTICLE	IF	CITATIONS
73	Clinical Impact of <i>NOTCH1</i> and/or <i>FBXW7</i> Mutations, <i>FLASH</i> Deletion, and <i>TCR</i> Status in Pediatric T-Cell Lymphoblastic Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1966-1973.	1.6	111
74	Extensive molecular mapping of <i>TCRβ</i> - and <i>TCRδ</i> -involved chromosomal translocations reveals distinct mechanisms of oncogene activation in T-ALL. <i>Blood</i> , 2012, 120, 3298-3309.	1.4	31
75	TLX Homeodomain Oncogenes Mediate T Cell Maturation Arrest in T-ALL via Interaction with ETS1 and Suppression of <i>TCRβ</i> Gene Expression. <i>Cancer Cell</i> , 2012, 21, 563-576.	16.8	81
76	Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 4476-4479.	1.4	96
77	Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of <i>NOTCH1</i> / <i>FBXW7</i> mutations, but not of low <i>ERG</i> / <i>BAALC</i> expression: a GRAALL study. <i>Blood</i> , 2011, 118, 5099-5107.	1.4	50
78	Posttranscriptional deregulation of <i>MYC</i> via <i>PTEN</i> constitutes a major alternative pathway of <i>MYC</i> activation in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 6650-6659.	1.4	72
79	<i>PTPN2</i> negatively regulates oncogenic <i>JAK1</i> in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 7090-7098.	1.4	76
80	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. <i>Blood</i> , 2010, 115, 3215-3223.	1.4	243
81	ALL-associated <i>JAK1</i> mutations confer hypersensitivity to the antiproliferative effect of type I interferon. <i>Blood</i> , 2010, 115, 3287-3295.	1.4	24
82	<i>JAK1</i> mutations are not frequent events in adult T-ALL: a GRAALL study. <i>British Journal of Haematology</i> , 2010, 148, 178-179.	2.5	47
83	Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2010, 207, 731-750.	8.5	169
84	Normal and Pathological V(D)J Recombination: Contribution to the Understanding of Human Lymphoid Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2009, 650, 180-194.	1.6	13
85	<i>C/EBPA</i> methylation is common in T-ALL but not in M0 AML. <i>Blood</i> , 2009, 113, 1864-1866.	1.4	6
86	<i>NOTCH1</i> / <i>FBXW7</i> mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. <i>Blood</i> , 2009, 113, 3918-3924.	1.4	207
87	Eight Colors Flow Cytometry Phenotyping for Blood Minimal Residual Disease Monitoring in Hairy Cell Leukaemia Patients.. <i>Blood</i> , 2009, 114, 1609-1609.	1.4	1
88	<i>NOTCH1</i> / <i>FBXW7</i> Mutations, but Not Low <i>ERG</i> / <i>BAALC</i> Expression, Identify a Major Subgroup of Adult T-ALL with a Favorable Outcome: a GRAALL Study.. <i>Blood</i> , 2009, 114, 1568-1568.	1.4	0
89	T Cell Receptor Genotyping and <i>HOXA</i> / <i>TLX1</i> Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome. <i>Clinical Cancer Research</i> , 2008, 14, 692-700.	7.0	43
90	Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of <i>TLX3</i> / <i>HOX11L2</i> gene expression on outcome. <i>Haematologica</i> , 2008, 93, 1658-1665.	3.5	57

#	ARTICLE	IF	CITATIONS
91	NOTCH1/FBXW7 Mutation Identifies a Large Subgroup with Favorable Outcome in Adult T-ALL: A GRAALL Study.. Blood, 2008, 112, 1494-1494.	1.4	2
92	Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood, 2007, 110, 2324-2330.	1.4	60
93	Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. Blood, 2007, 110, 388-392.	1.4	47
94	Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17). Blood, 2006, 108, 3484-3493.	1.4	34
95	Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood, 2005, 105, 3072-3078.	1.4	63
96	Prediction of Relapse Risk by Day 100 BCR-ABL Quantification after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukaemia.. Blood, 2005, 106, 2020-2020.	1.4	0
97	Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood, 2004, 104, 4173-4180.	1.4	94
98	Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology, 2003, 125, 730-745.	1.3	407
99	FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood, 2003, 102, 2198-2204.	1.4	90
100	Analysis of TCR, pTÎ±, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood, 2003, 101, 2693-2703.	1.4	152
101	CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCR $\alpha\alpha$ lineage. Blood, 2003, 102, 1000-1006.	1.4	148